Increased GABAA receptor binding in amygdala after prenatal administration of valproic acid to rats

被引:8
|
作者
Bertelsen, Freja [1 ,2 ,3 ]
Moller, Arne [1 ,2 ,3 ]
Folloni, Davide [1 ,4 ]
Drasbek, Kim Ryun [1 ]
Scheel-Kruger, Jorgen [1 ]
Landau, Anne M. [2 ,3 ,5 ]
机构
[1] Aarhus Univ, Ctr Funct Integrat Neurosci, Aarhus, Denmark
[2] Aarhus Univ & Hosp, Dept Nucl Med, Aarhus, Denmark
[3] Aarhus Univ & Hosp, PET Ctr, Aarhus, Denmark
[4] Univ Oxford, Dept Expt Psychol, Oxford, England
[5] Aarhus Univ, Translat Neuropsychiat Unit, Risskov, Denmark
关键词
C-11]Ro-154513; autism spectrum disorders; autoradiography; GABA; valproic acid; ANIMAL-MODEL; AUTISM; DISORDER; BRAIN; EXPOSURE; NEURONS; NUMBER;
D O I
10.1017/neu.2016.59
中图分类号
Q189 [神经科学];
学科分类号
071006 ;
摘要
Objective: Prenatal exposure to valproic acid (VPA) enhances the risk for later development of autism spectrum disorders (ASD). An altered gamma-aminobutyric acid (GABA) system may be a key factor in ASD. Here we investigated possible changes in the GABA system in rats exposed to a low dose of prenatal VPA. Method: We performed autoradiography with [H-3] muscimol, (a GABA(A) receptor agonist), and [C-11]Ro15-4513 (a partial agonist of the GABA(A) alpha(1+5) receptor subtypes), in brain sections containing amygdala, thalamus and hippocampus of rats treated prenatally with 20 mg/kg VPA or saline from the 12th day of gestation. Result: Prenatal VPA significantly increased [C-11]Ro15-4513 binding in the left amygdala compared with controls (p < 0.05). This difference was not observed in the hippocampus, thalamus or right amygdala. No differences were observed in [H-3] muscimol binding. Conclusion: We observed an asymmetric increase in GABAA receptor binding. Disturbances in the GABAA receptor system have also been detected in human autism with [C-11]Ro15-4513.
引用
收藏
页码:309 / 314
页数:6
相关论文
共 50 条
  • [1] Suppressed play behaviour and decreased oxytocin receptor binding in the amygdala after prenatal exposure to low-dose valproic acid
    Bertelsen, Freja
    Folloni, Davide
    Moller, Arne
    Landau, Anne M.
    Scheel-Krueger, Jorgen
    Winterdahl, Michael
    BEHAVIOURAL PHARMACOLOGY, 2017, 28 (06): : 450 - 457
  • [2] PERSISTENT ALTERATIONS IN GABAA RECEPTOR-BINDING AND FUNCTION AFTER PRENATAL LORAZEPAM ADMINISTRATION IN THE CHICK
    MILLER, LG
    ROY, RB
    WEILL, CL
    LOPEZ, F
    BRAIN RESEARCH BULLETIN, 1989, 23 (03) : 171 - 174
  • [3] Nociceptive changes in rats after prenatal exposure to valproic acid
    Schneider, T
    Labuz, D
    Przewlocki, R
    POLISH JOURNAL OF PHARMACOLOGY, 2001, 53 (05): : 531 - 534
  • [4] Hyperplasticity in the amygdala of rat Model by prenatal exposure to valproic acid
    Lin, Hui-Ching
    Chan, Yun-Han
    Chen, Po See
    FASEB JOURNAL, 2013, 27
  • [5] Regulation of gephyrin and GABAA receptor binding within the amygdala after fear acquisition and extinction
    Chhatwal, JP
    Myers, KM
    Ressler, KJ
    Davis, M
    JOURNAL OF NEUROSCIENCE, 2005, 25 (02): : 502 - 506
  • [6] The Developmental Gross Morphology of Pancreas in Chick Embryo after Prenatal Administration of Valproic Acid
    Akhtar, Lubna
    Khan, M. Yunus
    Minhas, Liaqat Ali
    JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2015, 25 (01): : 4 - 7
  • [7] BEHAVIORAL TERATOGENICITY OF VALPROIC ACID - SELECTIVE EFFECTS ON BEHAVIOR AFTER PRENATAL EXPOSURE TO RATS
    VORHEES, CV
    PSYCHOPHARMACOLOGY, 1987, 92 (02) : 173 - 179
  • [8] INCREASED MICROSOMAL IRREVERSIBLE BINDING OF PHENYTOIN BY VALPROIC ACID
    WANG, SL
    LAI, ML
    HUANG, JD
    BIOCHEMICAL PHARMACOLOGY, 1991, 42 (05) : 1143 - 1144
  • [9] Effects of salicylate on the pharmacokinetics of valproic acid after oral administration of sodium valproate in rats
    Ohshiro, S
    Hobara, N
    Sakai, M
    Hokama, N
    Kameya, H
    Sakanashi, M
    BIOGENIC AMINES, 2003, 17 (4-6) : 401 - 407
  • [10] Increased amygdala fMRI activation after secretin administration
    Yurgelun-Todd, Deborah A.
    Rogowska, Jadwiga
    Gruber, Staci A.
    Bogorodzki, Piotr
    Simpson, Norah S.
    Irvin, Robert W.
    Jauregui, Karen A.
    Strong, Richard A.
    Rusche, James R.
    EXPERIMENTAL AND CLINICAL PSYCHOPHARMACOLOGY, 2008, 16 (03) : 191 - 198